Jacob Asset Management of New York’s Krystal Biotech KRYS Stock Holding History

Jacob Asset Management of New York’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$493K	Sell	4,247 -400	-9%	-$48.8K	0.69%	43
2023 Q2	$546K	Sell	4,647 -2,619	-36%	-$267K	0.61%	46
2023 Q1	$582K	Buy	7,266 +329	+5%	+$25.8K	0.68%	44
2022 Q4	$550K	Buy	6,937 +3,175	+84%	+$236K	0.67%	43
2022 Q3	$262K	Sell	3,762 -965	-20%	-$69.7K	0.28%	53
2022 Q2	$310K	Sell	4,727 -29,515	-86%	-$1.84M	0.31%	54
2022 Q1	$2.28M	Sell	34,242 -16,680	-33%	-$1.04M	1.39%	26
2021 Q4	$3.56M	Buy	50,922 +25,878	+103%	+$1.51M	1.59%	20
2021 Q3	$1.31M	Buy	25,044 +8,144	+48%	+$482K	0.48%	50
2021 Q2	$1.15M	Hold	16,900	–	–	0.38%	58
2021 Q1	$1.3M	Buy	16,900 +7,000	+71%	+$509K	0.5%	52
2020 Q4	$594K	Buy	+9,900	New	+$494K	0.45%	44

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jacob Asset Management of New York's KRYS Position: Q3 2023 in Review

Jacob Asset Management of New York reduced its Krystal Biotech (KRYS) stake by 8.6% in Q3 2023, selling an estimated $48.8K and leaving 4,247 shares worth $493K. The position accounts for 0.69% of the portfolio, ranked #43.

Jacob Asset Management of New York first reported a position in KRYS in Q4 2020 and has held it in 12 quarters since. The position peaked at $3.56M in Q4 2021. 188 funds tracked by Wall St. Rank hold KRYS as of Q3 2023.

Jacob Asset Management of New York held 4,247 shares of Krystal Biotech worth $493K as of Q3 2023.
Jacob Asset Management of New York sold 400 Krystal Biotech shares in Q3 2023, an estimated $48.8K.
Krystal Biotech made up 0.69% of Jacob Asset Management of New York's portfolio in Q3 2023, its #43 holding.
Jacob Asset Management of New York first reported a position in Krystal Biotech in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's Krystal Biotech position peaked at $3.56M in Q4 2021.
188 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.